TTP-like syndrome: Novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease

Thrombosis Journal

Volumn 16, Issue 1, 2018, Pages

  Chang, Jae C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADAMTS13; Complement; Disseminated intravascular coagulation (DIC); Disseminated intravascular microthrombosis (DIT); Endotheliopathy; Microthrombogenesis; Thrombotic thrombocytopenic purpura (TTP); TTP like syndrome; Unusually large von Willbrand factor multimers (ULVWF); Vascular microthrombotic disease (VMTD)

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; COMPLEMENT ACTIVATION; CRITICALLY ILL PATIENT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; EXOCYTOSIS; HUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE; VASCULAR MICROTHROMBOTIC DISEASE;

EID: 85051493872     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-018-0174-4     Document Type: Review

References (131)

1. Chang JC. A Thought on Possible Pathogenesis of Ebola Viral Hemorrhagic Disease and Potential Treatments: Could it Be Thrombotic Thrombocytopenic Purpura-like Syndrome? Ther Apher Dial. 2015;20:93-8.
2. Chang JC. Thrombocytopenia in critically ill patients due to vascular microthrombotic disease: pathogenesis based on "two activation theory of the endothelium". Vascul Dis Ther. 2017;2:1-7.
3. Chang JC. Molecular pathogenesis of STEC-HUS caused by endothelial heterogeneity and unprotected complement activation, leading to endotheliopathy and impaired ADAMTS13 activity: based on two-activation theory of the endothelium and vascular microthrombotic disease. Nephrol Renal Dis. 2017;2:1-8.
4. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91:1-19.
5. Chauhan AK, Goerge T, Schneider SW, Wagner DD. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost. 2007;5:583-9.
6. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-9.
7. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Arch Intern Med. 1925;36:89-93.
8. Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses. Blood. 1947;2:542-54.
9. Sonneveld MA, de Maat MP, Portegies ML, et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015;126:2739-46.
10. Akyol O, Akyol S, Chen CH. Update on ADAMTS13 and VWF in cardiovascular and hematological disorders. Clin Chim Acta. 2016;463:109-18.
11. Chang JC, Newman RS. Redefining the syndromes of thrombotic microangiopathy. Ther Apher Dial. 2004;8:73-4.
12. Chang JC. The understanding of thrombotic thrombocytopenic purpura: Dyadic, triadic, pentadic, and other manifestations. J Clin Apher. 2004;19:2-4.
13. Chang JC, Kathula SK. Various clinical manifestations in patients with thrombotic microangiopathy. J Investig Med. 2002;50:201-6.
14. Sarode R. Atypical presentations of thrombotic thrombocytopenic purpura: a review. J Clin Apher. 2009;24:47-52.
15. Panackel C, Thomas R, Sebastian B, Mathai SK. Recent advances in management of acute liver failure. Indian J Crit Care Med. 2015;19:27-33.
16. Rath W, Faridi A, Dudenhausen JW. HELLP syndrome. J Perinat Med. 2000;28:249-60.
17. Wahla AS, Ruiz J, Noureddine N, Upadhya B, Sane DC, Owen J. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol. 2008;81:311-6.
18. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion. 2008;48:382-92.
19. Bone RC, Henry JE, Petterson J, et al. Respiratory dysfunction in thrombotic thrombocytopenic purpura. Am J Med. 1978;65:262-70.
20. Chang JC, Aly ES. Acute respiratory distress syndrome as a major clinical manifestation of thrombotic thrombocytopenic purpura. Am J Med Sci. 2001;321:124-8.
21. Swisher KK, Doan JT, Vesely SK, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica. 2007;92:936-43.
22. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-5.
23. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-34.
24. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4.
25. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223-9.
26. Chang JC. Disseminated intravascular coagulation: is it fact or fancy? Blood Coagul Fibrinolysis. 2018;29:3030-7.
27. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol. 2001;16:823-39.
28. Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep. 2017;9:7053.
29. Takimoto T, Nakao M, Nakajo T, Chinen Y, Kuroda J, Taniwaki M. Acute myocardial infarction as the initial thrombotic event of thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2016;27:948-51.
30. Atreya AR, Arora S, Sivalingam SK, Giugliano GR. ST segment elevation myocardial infarction as a presenting feature of thrombotic thrombocytopenic purpura. J Cardiovasc Dis Res. 2012;3:167-9.
31. McDonald V, Laffan M, Benjamin S, Bevan D, Machin S, Scully MA. Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol. 2009;144:430-3.
32. Muñiz AE, Barbee RW. Thrombotic thrombocytopenic purpura (TTP) presenting as pancreatitis. J Emerg Med. 2003;24:407-11.
33. Qahtani SA. Acute renal failure and severe rhabdomyolysis in a patient with resistant thrombotic thrombocytopenic purpura. Int J Gen Med. 2011;4:687-9.
34. Ikhlaque N, Chang JC. Thrombotic Microangiopathy presenting as fulminating rhabdomyolysis with multiorgan dysfunction. Hospital Physician. 2003;39(6):51-6.
35. Burrus TM, Mandrekar J, Wijdicks EF, Rabinstein AA. Renal failure and posterior reversible encephalopathy syndrome in patients with thrombotic thrombocytopenic purpura. Arch Neurol. 2010;67:831-4.
36. Bakshi R, Shaikh ZA, Bates VE, Kinkel PR. Thrombotic thrombocytopenic purpura: brain CT and MRI findings in 12 patients. Neurology. 1999;52:1285-8.
37. Vaziri S, Navabi J, Afsharian M, et al. Crimean congo hemorrhagic fever infection simulating thrombotic thrombocytopenic purpura. Indian J Hematol Blood Transfus. 2008;24:35-8.
38. Deepanjali S, Naik RR, Mailankody S, Kalaimani S, Kadhiravan T. Dengue Virus Infection Triggering Thrombotic Thrombocytopenic Purpura in Pregnancy. Am J Trop Med Hyg. 2015;93:1028-30.
39. Ardalan MR, Tubbs RS, Chinikar S, Shoja MM. Crimean-Congo haemorrhagic fever presenting as thrombotic microangiopathy and acute renal failure. Nephrol Dial Transplant. 2006;21:2304-7.
40. Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther. 2011;4(2):51-9.
41. Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011;86:743-51.
42. Chang JC, Shipstone A, Llenado-Lee MA. Postoperative thrombotic thrombocytopenic purpura following cardiovascular surgeries. Am J Hematol. 1996;53:11-7.
43. Naqvi TA, Baumann MA, Chang JC. Post-operative thrombotic thrombocytopenic purpura: a review. Int J Clin Pract. 2004;58:169-72.
44. Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1:9.
45. Tsirigotis P, Chondropoulos S, Frantzeskaki F, et al. Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile. J Crit Care. 2016;32:9-15.
46. Kutcher ME, Redick BJ, McCreery RC, et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg. 2012;73:13-9.
47. Shamseddine A, Chehal A, Usta I, Salem Z, El-Saghir N, Taher A. Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review. J Clin Apher. 2004;19:5-10.
48. Nguyen TC, Carcillo JA. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill. Crit Care. 2006;10:235.
49. Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lisman T, Lee WM. Acute liver failure study group. Thromobcytopenia is associated with multi-organ system failure in patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14:613-20.
50. Nydam TL, Kashuk JL, Moore EE, et al. Refractory post-injury thrombocytopenia is associated with multiple organ failure and adverse outcomes. J Trauma 2011;70:401-406; discussion 406-7.
51. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol. 2008;6:132-42.
52. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J Cell Mol Med. 2008;12:2245-54.
53. Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology. 2012;217:195-203.
54. Davies A, Lachmann PJ. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res. 1993;12:258-75.
55. Gene Cards. CD59 gene. http://www.genecards.org/cgi-bin/carddisp.pl?gene=CD59
56. Levi M, Löwenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2008;34:417-24.
57. Mollnes TE, Fosse E. The complement system in trauma-related and ischemic tissue damage: a brief review. Shock. 1994;2:301-10.
58. Gilbert JS, Banek CT, Katz VL, Babcock SA, Regal JF. Complement activation in pregnancy: too much of a good thing? Hypertension. 2012;60:1114-6.
59. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542-8.
60. Baldwin WM, Ota H, Rodriguez ER. Complement in transplant rejection: diagnostic and mechanistic considerations. Springer Semin Immunopathol. 2003;25:181-97.
61. Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest. 2017;127:780-9.
62. Ostrowski SR, Haase N, Müller RB, et al. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study. Crit Care. 2015;19:191.
63. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008;103:398-406.
64. van Ierssel SH, Jorens PG, Van Craenenbroeck EM, Conraads VM. The endothelium, a protagonist in the pathophysiology of critical illness: focus on cellular markers. Biomed Res Int. 2014;2014:985813.
65. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765-77.
66. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis--a systematic review. Crit Care. 2012;16:R7.
67. van den Born BJ, Löwenberg EC, van der Hoeven NV, de Laat B, Meijers JC, Levi M, van Montfrans GA. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29:922-7.
68. Bockmeyer CL, Claus RA, Budde U, et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica. 2008;93:137-40.
69. Valentijn KM, van Driel LF, Mourik MJ, et al. Multigranular exocytosis of Weibel-Palade bodies in vascular endothelial cells. Blood. 2010;116:1807-16.
70. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3:562-70.
71. Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011;9(Suppl 2):s3-8.
72. Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25:206-16.
73. Dhanesha N, Prakash P, Doddapattar P, et al. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation. Arterioscler Thromb Vasc Biol 2016. 36:1829-37.
74. Verhenne S, Denorme F, Libbrecht S, et al. Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood. 2015;126:1715-22.
75. Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2013;2013:292-9.
76. Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 2007;92:121-4.
77. Feng S, Eyler SJ, Zhang Y, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013;122:1487-93.
78. Pourrat O, Coudroy R, Pierre F. ADAMTS13 deficiency in severe postpartum HELLP syndrome. Br J Haematol. 2013;163:409-10.
79. Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood. 2012;120:5224-30.
80. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2010;115:1650-3.
81. Yu WL, Leung T, Soo Y, Lee J, Wong KS. Thrombotic thrombocytopenic purpura with concomitant small- and large-vessel thrombosis, atypical posterior reversible encephalopathy syndrome and cerebral microbleeds. Oxf Med Case Reports. 2015;2015:179-82.
82. Ibernon M, Moreso F, Carreras L, et al. Thrombotic thrombocytopenic purpura with severe large artery branch involvement. Nephrol Dial Transplant. 2005;20:467-8.
83. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem. 1993;268:15484-8.
84. Nolan DJ, Ginsberg M, Israely E, et al. Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev Cell. 2013;26:204-19.
85. Aird WC. Endothelial Cell Heterogeneity. Cold Spring Harb Perspect Med. 2012;2:a006429.
86. Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res. 2001;50:163-71.
87. Cooperberg AA. Acute promyelocytic leukemia. Can Med Assoc J. 1967;97:57-63.
88. Dunoyer-Geindre S, Rivier-Cordey AS, Tsopra O, Lecompte T, Kruithof EKO. Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β. Ann Hematol. 2017;96:905-17.
89. Levi M, van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost. 2014;40:874-80.
90. McKay DG. Progress in disseminated intravascular coagulation. Calif Med. 1969;111:186-198 contd.
91. McKay DG. Progress in disseminated intravascular coagulation part II. Calif Med. 1969;111:279-90.
92. Sueishi K, Takeuchi M. Pathology of disseminated intravascular coagulation. Nihon Rinsho. 1993;51:30-6.
93. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037.
94. Boral BM, Williams DJ, Boral LI. Disseminated Intravascular Coagulation. Am J Clin Pathol. 2016;146:670-80.
95. Wu Y, Luo L, Niu T, et al. Evaluation of the new Chinese Disseminated Intravascular Coagulation Scoring System in critically ill patients: A multicenter prospective study. Sci Rep. 2017;7:9057.
96. Toh CH, Alhamdi Y, Abrams ST. Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation. Ann Lab Med. 2016;36:505-12.
97. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131:845-54.
98. Kotiah SD. Besa EC. Acute promyelocytic leukemia clinical presentation. http://emedicine.medscape.com/article/1495306-clinical
99. Chang JC, Gross HM, Jang NS. Disseminated intravascular coagulation due to intravenous administration of hetastarch. Am J Med Sci. 1990;300:301-3.
100. He B, Hu S, Qiu G, Gu W. Clinical characteristics of acute promyelocytic leukemia manifesting as early death. Mol Clin Oncol. 2013;1:908-10.
101. Daver N, Kantarjian H, Marcucci G, et al. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015;168:646-53.
102. Kaneko T, Wada H. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop. 2011;5:67-76.
103. Slofstra SH, Spek CA, ten Cate H. Disseminated intravascular coagulation. Hematol J. 2003;4:295-302.
104. Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J. 2006;4:4.
105. Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost. 2013;11(Suppl 1):277-84.
106. Versteeg HH, Ruf W. Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr Opin Hematol. 2011;18:343-8.
107. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170-5.
108. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-30.
109. Petäjä J. Inflammation and coagulation. An overview. Thromb Res. 2011;127(Suppl 2):S34-7.
110. Demetz G, Ott I. The Interface between Inflammation and Coagulation in Cardiovascular Disease. Int J Inflam. 2012;2012:860301.
111. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-34.
112. Taylor FB Jr, Wada H, Kinasewitz G. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: toward a better definition of DIC. Crit Care Med. 2000;28(9 Suppl):S12-9.
113. Taylor FB Jr, Kinasewitz GT. The diagnosis and management of disseminated intravascular coagulation. Curr Hematol Rep. 2002;1:34-40.
114. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40:2704-8.
115. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195-203.
116. Kularatne SA, Imbulpitiya IV, Abeysekera RA, Waduge RN, Rajapakse RP, Weerakoon KG. Extensive haemorrhagic necrosis of liver is an unpredictable fatal complication in dengue infection: a postmortem study. BMC Infect Dis. 2014;14:141.
117. Talwani R, Gilliam BL, Howell C. Infectious diseases and the liver. Clin Liver Dis. 2011;15:111-30.
118. Samanta J, Sharma V. Dengue and its effects on liver. World J Clin Cases. 2015;3:125-31.
119. El Sayed SM, Abdelrahman AA, Ozbak HA, et al. Updates in diagnosis and management of Ebola hemorrhagic fever. J Res Med Sci. 2016;21:84.
120. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am. 1992;6:1247-57.
121. Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis. Int J Hepatol. 2011;2011:759047.
122. van Dongen PW, Eskes TK, Gimbrère JS, Snel P. Maternal mortality due to the hepatorenal syndrome of pre-eclampsia. A case report. Eur J Obstet Gynecol Reprod Biol. 1979;9:299-306.
123. Isler CM, Rinehart BK, Terrone DA, May WL, Magann EF, Martin JN Jr. The importance of parity to major maternal morbidity in the eclamptic mother with HELLP syndrome. Hypertens Pregnancy. 2003;22:287-94.
124. Agarwal B, Wright G, Gatt A, Riddell A, Vemala V, Mallett S, Chowdary P, Davenport A, Jalan R, Burroughs A. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol. 2012;57:780-6.
125. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol. 2006;12:7725-36.
126. Malla K, Malla T, Hanif M. Prognostic indicators in haemolytic uraemic syndrome. Kathmandu Univ Med J (KUMJ). 2004;2:291-6.
127. Tsai MH, Peng YS, Chen YC, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43:673-81128.
128. Franchini M, Manzato F, Salvagno GL, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007;18:589-93.
129. Román E, Mendizábal S, Jarque I, et al. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrologia. 2017;37:478-91.
130. Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J. 2017;10:600-24.
131. Nangaku M, Alpers CE, Pippin J. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol. 1998;9:590-7.